logo
Plus   Neg
Share
Email

Lilly, Incyte: CHMP Adopts Positive Opinion For Baricitinib In Treatment Of Atopic Dermatitis

Eli Lilly and Co. (LLY) and Incyte Corp. (INCY) said Friday that that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

The companies noted that the opinion marks the first step toward European regulatory approval for baricitinib (marketed as Olumiant) for patients with AD. If approved, baricitinib would become the first JAK inhibitor indicated to help treat patients with AD.

The CHMP opinion is now referred for action to the European Commission, which grants approval in the European Union. The companies expect a final decision from the European Commission in the next one to two months.

The positive CHMP opinion for baricitinib was based on Lilly's Phase 3 BREEZE-AD clinical development program for baricitinib evaluating the medicine's potential to treat AD.

This includes BREEZE-AD1 and BREEZE-AD2, monotherapy studies investigating the efficacy and safety of baricitinib in moderate to severe AD patients; and BREEZE-AD4, a study to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate to severe AD who have failed or who are intolerant to, or have contraindications to cyclosporine.

It also includes BREEZE-AD7, a study evaluating the efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate to severe AD.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT